The US Food and Drug Administration FDA has approved Symbravo, an oral combination of meloxicam and rizatriptan, for the ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS ...

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Axsome Therapeutics (AXSM) to $137 from $122 and keeps an Outperform rating ...

FDA approves Symbravo for acute migraine relief, combining rizatriptan and meloxicam. Discover its unique benefits and fast absorption for effective symptom control.

Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company with a market capitalization of $5.2 billion focused on developing novel therapies for central nervous system (CNS) disorders, has ...